According to Pfizer, the COVID-19 vaccine will cost between $110 and $130 per dose.
After the United States government stops purchasing the shots, Pfizer will charge between $110 and $130 for a dosage of its COVID-19 vaccine, while the pharmaceutical company anticipates that many people will continue to receive it for free.
According to Pfizer executives, the commercial pricing for adult doses might begin as early as next year, depending on when the government eventually ends its program of purchasing and delivering the shots.
Those who have private health insurance or coverage through government programs like Medicare or Medicaid won’t pay anything, according to the drugmaker. According to the Affordable Care Act, many recommended vaccinations must be covered by insurance without any out-of-pocket costs.
According to a representative, the business also offers qualified Americans without insurance access to its income-based assistance program, which helps them receive vaccinations.
The two-dose vaccine would cost more than yearly flu jabs for clients who pay with cash. According to CVS Health, which operates one of the major drugstore chains in the country, those can cost anywhere between $50 and $95, depending on the type.
The cost of transitioning to single-dose vials and commercial distribution, a Pfizer executive said on Thursday, is reflected in the pricing. For “what would be deemed a highly effective vaccine,” according to the CEO Angela Lukin, the price was far below the standards.
Last year, the pharmaceutical company said that it was charging $19.50 per dose in the United States and that, depending on each country’s financial circumstances, its global price was divided into three categories. The business announced in June that the US government would purchase an additional 105 million doses in a deal that would cost about $30 for each shot. After that, the government has the choice to buy more quantities.
The two-shot vaccination from Pfizer, which made its debut in late 2020, has been the most widely used COVID-19 preventative injection in the United States.
The Centers for Disease Control and Prevention estimates that more than 375 million doses of the initial vaccine, which Pfizer and the German pharmaceutical company BioNTech produced, have been given out in the United States.
An upgraded booster that was approved earlier this year will be given another 12 million times, though. The vaccine was Pfizer’s best-selling product last year and generated $36.78 billion in sales for the pharmaceutical company.
According to FactSet, analysts expect an additional $32 billion to be earned this year. But they also anticipate a sharp decline in sales following that.
According to the CDC, the COVID-19 vaccination has previously been administered to more than 90% of adult Americans. Only approximately half of this population, however, has additionally had a booster shot.